Posted by Michael Wonder on 26 Mar 2018
Shingrix approved in Europe and Japan for the prevention of shingles in adults aged 50 and over
23 March 2018 - The only shingles vaccine to achieve ≥90% efficacy across all age groups studied.
GlaxoSmithKline today announced that the European Commission has approved Shingrix for the prevention of shingles (herpes zoster) and post-herpetic neuralgia in adults aged 50 years or older. The Japanese Ministry of Health, Labour and Welfare has also approved Shingrix for the prevention of shingles (herpes zoster) in adults aged 50 years or older.
Shingrix is a non-live, recombinant subunit adjuvanted vaccine given intramuscularly in two doses.
